Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 4Whole-Body Irradiation 3Rituximab 3Etoposide 3Cytarabine 3Carmustine 3Therapeutics 2Tacrolimus 2Saline Solution 2Radiotherapy 2Polymerase Chain Reaction 2Pentetic Acid 2O(6)-benzylguanine 2Methotrexate 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fibroblast Growth Factor 7 2Dexamethasone 2Busulfan 2sargramostim 1romidepsin 1plerixafor 1pembrolizumab 1merphos 1fludarabine 1ferric pyrophosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hodgkin Disease × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00389506 2012-03-16

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase NA Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡